Sanofi: CHMP greenlights Libtayo
(CercleFinance.com) - The Committee for medicinal products for human use (CHMP) of the European Medicines Agency (EMA) has issued a favourable opinion on Sanofi's application to market Libtayo (cemiplimab), which it jointly develops with Regeneron.
The CHMP recommended its conditional approval in the treatment of metastatic or locally-advanced squamous cell carcinoma (CEC) in patients who are not candidates for surgery or curative radiation therapy.
Libtayo will be the first and only medicine indicated for the treatment of certain categories of patients with advanced-stage CEC in the European Union.
Note that this is one of the most frequently diagnosed skin cancers in the world.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
The CHMP recommended its conditional approval in the treatment of metastatic or locally-advanced squamous cell carcinoma (CEC) in patients who are not candidates for surgery or curative radiation therapy.
Libtayo will be the first and only medicine indicated for the treatment of certain categories of patients with advanced-stage CEC in the European Union.
Note that this is one of the most frequently diagnosed skin cancers in the world.
Copyright (c) 2019 CercleFinance.com. All rights reserved.